Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain.
Toxicity prevents the systemic administration of many therapeutic proteins, and attempts at protein targeting via the circulatory system (i.e., "magic bullets") have failed in all but a few special cases. Direct administration at the target site is a logical alternative, particularly in the central nervous system, but the limits of direct administration have not been defined clearly. Nerve growth factor (NGF) enhances survival of cholinergic neurons and, therefore, has generated considerable interest for the treatment of Alzheimer's disease. We tested the effectiveness of local delivery by implanting small polymer pellets that slowly released NGF into the central nervous system of adult rats at controlled distances from a target site containing transplanted fetal cholinergic cells. NGF-releasing implants placed within 1-2 mm of the treatment site enhanced the biological function of cellular targets, whereas identical implants placed approximately 3 mm from the target site of treatment produced no beneficial effect. Effective NGF therapy required millimeter-scale positioning of the NGF source, and efficacy correlated with the spatial distribution of NGF concentration in the tissue; this result suggests that NGF must be delivered within several millimeters of the target to be effective in treating Alzheimer's disease. Because the human brain is divided into functional regions that are typically several centimeters in diameter and often irregular in shape, new methods for sculpting larger-scale drug fields are needed. We illustrate a concept, called pharmacotectonics, in which drug-delivery systems are arranged spatially in tissues to shape concentration fields for potent agents.
Mahoney
M J
MJ
School of Chemical Engineering, Cornell University, Ithaca, NY 14853, USA.
Saltzman
W M
WM
D000818:Animals; D001704:Biopolymers; D016380:Brain Tissue Transplantation / Q000502:physiology*; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D003692:Delayed-Action Preparations; D004343:Drug Implants; D016332:Fetal Tissue Transplantation / Q000502:physiology*; D005333:Fetus; D006801:Humans; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D009474:Neurons / Q000502:physiology / Q000637:transplantation; D051381:Rats; D017207:Rats, Sprague-Dawley
D001704:Biopolymers; D003692:Delayed-Action Preparations; D004343:Drug Implants; D009414:Nerve Growth Factors; D002795:Choline O-Acetyltransferase